Still’s Disease Treatment Market Size to Exceed USD 2.79 Bn by 2032

The Still’s Disease Treatment Market, estimated at USD 2.01 Bn in 2025, is expected to exhibit a CAGR of 4.8% and reach USD 2.79 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The strategies adopted by key market players like new treatments for Still’s disease are expected to drive the global Still’s disease treatment market growth over the forecast period. For instance, on August 25, 2021, AB2 Bio Ltd, a clinical-stage biotechnology company, stated tadekinig alfa is also Phase 3-ready for Still’s Disease. It has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of HLH and Still’s disease, including adult-onset Still’s disease and systemic juvenile idiopathic arthritis, and by the European Medicines Agency (EMA) for the treatment of hemophagocytic lymphohistiocytosis. In addition, the U.S FDA has been granted breakthrough therapy designation for the treatment of monogenic, IL-18 associated autoinflammatory conditions with ongoing systemic inflammation, and rare pediatric disease designation for the treatment of primary hemophagocytic lymphohistiocytosis.

Global Still’s Disease Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems regarding the transportation of drugs from one place to another.

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 has affected the economy in three main ways:  directly affecting production and demand, causing disruptions in distribution channels, and through economic effects on businesses and financial markets. Due to the lockdown, several countries like India, China, Brazil and others faced problems in transporting drugs from one place to another.

COVID-19 had a positive impact on the global Still’s disease treatment market. For instance, according to an article published by the National Center for Biotechnology Information, on October 3, 2021, adult-onset Still’s disease is considered a rare inflammatory disease affecting young adults and IL-1 plays a central role in pathogenesis. Blocking IL-1β with monoclonal antibodies and blocking the IL-1 receptor with antagonists significantly improves clinical symptoms. Increasing evidence suggests that IL-1 plays a similar role in the hyperinflammation of COVID-19, and several reports suggest that it blocks IL-1. receptor-1. Significantly reduces hyperinflammation, respiratory failure, and mortality in hospitalized patients with severe COVID-19.

Global Still’s Disease Treatment Market: Key Developments

Increasing government approvals are expected to drive the global Still’s disease treatment market growth.

For instance, on June 16, 2020, Novartis, a pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Ilaris (canakinumab) injection for the treatment of active Still’s disease including Adult-onset Still’s Disease (AOSD). Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older. AOSD is a rare and severe auto inflammatory disease of unknown origin. Autoinflammatory diseases are caused by disorders of the immune system that trigger an inflammatory response that can damage the body's own tissues.  AOSD has significant overlap with Systemic Juvenile Idiopathic Arthritis (SJIA), which includes fever, arthralgia, rash, and elevated inflammatory markers. The overlapping features of AOSD and SJIA suggest that are a continuum of disorders rather than two distinct disorders.

Browse 40 Market Data Tables and 48 Figures spread through 255 Pages and in-depth TOC on Global Still’s Disease Treatment Market, By Treatment (Pain Management, Corticosteroids, Tocilizumab, Canakinumab, and Others), By Route of Administration (Injectables and Oral), By Distribution Channels (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/stills-disease-treatment-market-4023

Key Takeaways of the Global Still’s Disease Treatment Market:

• The global Still’s disease treatment market is expected to exhibit a CAGR of 4.8% during the forecast period due to increasing treatments for still’s disease. For instance, on February 3, 2023, Elsevier Journal published data stating Non-steroidal Anti-inflammatory Drugs (NSAIDs) are often offered to patients awaiting diagnosis before first-line therapy. Once the diagnosis is made, corticosteroids, especially glucocorticoids, are usually used as the first-line therapy for AOSD and are effective in controlling the disease in about 60-65% of patients, with usually greater efficacy in patients with systemic disease. The initial response to glucocorticoids is usually good, although high doses of glucocorticoids sometimes fail to induce remission. However, glucocorticoid toxicity causes iatrogenic problems, and decreased glucocorticoid levels often cause relapse.
• Among route of administration, the oral segment is expected to dominate the global Still’s disease treatment market over the forecast period, owing to increasing treatments of oral drugs. For instance, on April 3, 2023 Springer journal, published an article stating female patients with refractory adult-onset still’s disease received baricitinib. The median age was 31 Treatment was terminated in one patient due to progressive Macrophage Activation Syndrome (MAS). Baricitinib therapy could provide rapid and durable clinical and laboratory improvement in patients with refractory AOSD. Treatment seemed to be well tolerated by these patients.
• Among region, North America is expected to be the dominant region in the global Still’s disease treatment market, owing to the increasing approvals for treatment for still’s disease treatment in the region. For instance, on April 29, 2021, Novartis Pharmaceuticals Inc., a pharmaceutical company announced that Health Canada, department of the Government of Canada approved Ilaris (canakinumab) for the treatment of active Still's disease, including Adult-onset Still's Disease (AOSD). AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications.
• The major players operating in the global Still’s disease treatment market include AB2 Bio Ltd, F.Hoffmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V, Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd, and Fresenius Kabi AG.